Neutrophils are key players in innate immunity and represent the most abundant population of white blood cells in human blood. As first responders to infection, they neutralize pathogens through various mechanisms, including the formation of NETs (Neutrophil Extracellular Traps), true “nets” capable of capturing and eliminating bacteria and fungi. Their study is essential for better understanding inflammatory processes, autoimmune diseases, and certain cancer-related pathologies.
However, labeling neutrophils remains a challenge: many existing methods can alter or activate these cells, thereby modifying their behavior and potentially biasing analyses. Developed by Bertin Bioreagent, Myelotracker provides an innovative solution to this issue through a peptide-based technology that specifically targets lactoferrin, a protein naturally present in neutrophils. This approach enables precise and selective detection without disrupting their physiological state.
The performance of Myelotracker is demonstrated in our dedicated Application Note, highlighting its ability to efficiently label neutrophils from human samples, even under native conditions and in the presence of NETs. A major advancement for researchers in immunology, inflammation, oncology, and biomedical research seeking reliable results that accurately reflect real biological conditions.
